Aug 19 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:
ALDEYRA THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FOR ADX‑2191 FOR THE TREATMENT OF RETINITIS PIGMENTOSA
ALDEYRA THERAPEUTICS INC - PHASE 2/3 TRIAL OF ADX-2191 EXPECTED TO START IN 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.